KROS Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Zacks Investment Research - Mentions: AXS GLDD ENS STNE

Buy These 5 Best Value Stocks to Make the Most of P/B Ratio

8 days ago - By: Zacks Investment Research

KROS or NVZMY: Which Is the Better Value Stock Right Now?

8 days ago - By: Zacks Investment Research

How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%

14 days ago - By: Keros Therapeutics, Inc.

Keros Therapeutics Announces Final Results of Tender Offer

15 days ago - By: Keros Therapeutics, Inc.

Keros Therapeutics Announces Preliminary Results of Tender Offer

24 days ago - By: Zacks Investment Research - Mentions: ARGX

KROS vs. ARGX: Which Stock Is the Better Value Option?

21 days ago - By: Zacks Investment Research - Mentions: GLDD ENS STNE MLKN

5 Undervalued Stocks That Are Poised for Growth in November

24 days ago - By: Zacks Investment Research

Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High?

a month ago - By: Zacks Investment Research - Mentions: BNGO

Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates

a month ago - By: Keros Therapeutics, Inc.

Keros Therapeutics Reports Third Quarter 2025 Financial Results

2 months ago - By: Keros Therapeutics, Inc.

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

3 months ago - By: Keros Therapeutics, Inc.

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

4 months ago - By: ADAR1 Capital Management, LLC

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

4 months ago - By: Keros Therapeutics, Inc.

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

4 months ago - By: Zacks Investment Research - Mentions: YMAB

Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: Keros Therapeutics, Inc.

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

4 months ago - By: Keros Therapeutics, Inc.

Keros Therapeutics Reports Second Quarter 2025 Financial Results

6 months ago - By: Yahoo Finance - Mentions: MSFT DUOL ATEN ASML ...

Billionaire has a three-word blunt response to the falling dollar

6 months ago - By: Yahoo Finance - Mentions: BAC VZ ARCB LMNR ...

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

6 months ago - By: Benzinga

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

6 months ago - By: Yahoo Finance - Mentions: RY RY.CA BA BAC ...

Equity Markets Rise Intraday as US-China Trade Talks Continue

6 months ago - By: Yahoo Finance - Mentions: RJF LMNR MCD EGBN ...

McDonald's downgraded on GLP-1 drug worries: Wall Street's top analyst calls

6 months ago - By: ADAR1 Capital Management, LLC

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

6 months ago - By: Keros Therapeutics, Inc.

Keros Announces Return of $375 Million in Excess Capital to Stockholders

6 months ago - By: Keros Therapeutics, Inc.

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

6 months ago - By: Yahoo Finance - Mentions: KR

C&S ventures into international supply chain market with new partnership

6 months ago - By: Yahoo Finance - Mentions: CADL PFE VREX CTKB ...

Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer

6 months ago - By: Yahoo Finance - Mentions: CTKB MS PFGC CRM ...

Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System

6 months ago - By: Yahoo Finance - Mentions: PFE CADL XRX KC ...

Pfizer Inc. (PFE) Ends Acepodia Partnership Amid Depo-Provera Legal Woes

6 months ago - By: Yahoo Finance - Mentions: REVB ESLT CTKB VREX ...

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

6 months ago - By: Yahoo Finance - Mentions: VREX CTKB CADL CI ...

Varex Imaging Corporation (VREX) Downgraded by S&P as Regulatory Outlook Remains Cloudy

6 months ago - By: Yahoo Finance - Mentions: VRNA NEXT VFC SONY ...

Jim Cramer Notes Verona Pharma plc (VRNA) “Loses a Lot of Money”

6 months ago - By: Yahoo Finance - Mentions: NPCE IVVD ENPH HOWL ...

H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating

6 months ago - By: Yahoo Finance - Mentions: IVVD NPCE HOWL THC ...

KEROS THERAPEUTICS INC (KROS) Stock News

KROS Latest News, Press Relases and Analysis

Buy These 5 Best Value Stocks to Make the Most of P/B Ratio

KROS or NVZMY: Which Is the Better Value Stock Right Now?

How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%

Keros Therapeutics Announces Final Results of Tender Offer

Keros Therapeutics Announces Preliminary Results of Tender Offer

KROS vs. ARGX: Which Stock Is the Better Value Option?

5 Undervalued Stocks That Are Poised for Growth in November

Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High?

Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates

Keros Therapeutics Reports Third Quarter 2025 Financial Results

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Keros Therapeutics Reports Second Quarter 2025 Financial Results

Billionaire has a three-word blunt response to the falling dollar

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

Equity Markets Rise Intraday as US-China Trade Talks Continue

McDonald's downgraded on GLP-1 drug worries: Wall Street's top analyst calls

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

Keros Announces Return of $375 Million in Excess Capital to Stockholders

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

C&S ventures into international supply chain market with new partnership

Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer

Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System

Pfizer Inc. (PFE) Ends Acepodia Partnership Amid Depo-Provera Legal Woes

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

Varex Imaging Corporation (VREX) Downgraded by S&P as Regulatory Outlook Remains Cloudy

Jim Cramer Notes Verona Pharma plc (VRNA) “Loses a Lot of Money”

H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating

H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall